Cargando…

Genomic alterations of cerebrospinal fluid cell-free DNA in leptomeningeal metastases of gastric cancer

BACKGROUND: Leptomeningeal metastases (LM) were rare in gastric cancer (GC), and GC patients with LM (GCLM) generally suffer from poor prognosis. Nevertheless, the clinical utility of cerebrospinal fluid (CSF) circulating tumor DNA (ctDNA) was underinvestigated in GCLM. METHODS: We retrospectively s...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xin, Bai, Kaixuan, Zhang, Yu, Xu, Yang, Huo, Yinghao, Wang, Sha, Zou, Yueli, Qi, Xuejiao, Guo, Rongyun, Ou, Qiuxiang, Liu, Dengxiang, Yin, Shaohua, Chen, Shubo, Bu, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10155444/
https://www.ncbi.nlm.nih.gov/pubmed/37131253
http://dx.doi.org/10.1186/s12967-023-04077-8
_version_ 1785036329865707520
author Chen, Xin
Bai, Kaixuan
Zhang, Yu
Xu, Yang
Huo, Yinghao
Wang, Sha
Zou, Yueli
Qi, Xuejiao
Guo, Rongyun
Ou, Qiuxiang
Liu, Dengxiang
Yin, Shaohua
Chen, Shubo
Bu, Hui
author_facet Chen, Xin
Bai, Kaixuan
Zhang, Yu
Xu, Yang
Huo, Yinghao
Wang, Sha
Zou, Yueli
Qi, Xuejiao
Guo, Rongyun
Ou, Qiuxiang
Liu, Dengxiang
Yin, Shaohua
Chen, Shubo
Bu, Hui
author_sort Chen, Xin
collection PubMed
description BACKGROUND: Leptomeningeal metastases (LM) were rare in gastric cancer (GC), and GC patients with LM (GCLM) generally suffer from poor prognosis. Nevertheless, the clinical utility of cerebrospinal fluid (CSF) circulating tumor DNA (ctDNA) was underinvestigated in GCLM. METHODS: We retrospectively studied 15 GCLM patients, and all patients had paired primary tumor tissue samples and post-LM CSF samples while 5 patients also had post-LM plasma samples. All samples were analyzed using next-generation sequencing (NGS), and the molecular and clinical features were correlated with clinical outcomes. RESULTS: CSF had higher mutation allele frequency (P = 0.015), more somatic mutations (P = 0.032), and more copy-number variations (P < 0.001) than tumor or plasma samples. Multiple genetic alterations and aberrant signal pathways were enriched in post-LM CSF, including CCNE1 amplification and cell cycle-related genes, and CCNE1 amplification was significantly associated with patients’ overall survival (P = 0.0062). More potential LM progression-related markers were detected in CSF samples than in tumor samples, including PREX2 mutation (P = 0.014), IGF1R mutation (P = 0.034), AR mutation (P = 0.038), SMARCB1 deletion (P < 0.001), SMAD4 deletion (P = 0.0034), and TGF-beta pathway aberration (P = 0.0038). Additionally, improvement in intracranial pressure (P < 0.001), improvement in CSF cytology (P = 0.0038), and relatively low levels of CSF ctDNA (P = 0.0098) were significantly associated with better PFS. Lastly, we reported a GCLM case whose CSF ctDNA dynamic changes were well correlated with his clinical assessment. CONCLUSIONS: CSF ctDNA could more sensitively detect molecular markers and metastasis-related mechanisms than tumor tissues in GCLM patients, and our study sheds light on utilizing CSF ctDNA in prognostic estimation and clinical assessment in GCLM. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-023-04077-8.
format Online
Article
Text
id pubmed-10155444
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-101554442023-05-04 Genomic alterations of cerebrospinal fluid cell-free DNA in leptomeningeal metastases of gastric cancer Chen, Xin Bai, Kaixuan Zhang, Yu Xu, Yang Huo, Yinghao Wang, Sha Zou, Yueli Qi, Xuejiao Guo, Rongyun Ou, Qiuxiang Liu, Dengxiang Yin, Shaohua Chen, Shubo Bu, Hui J Transl Med Research BACKGROUND: Leptomeningeal metastases (LM) were rare in gastric cancer (GC), and GC patients with LM (GCLM) generally suffer from poor prognosis. Nevertheless, the clinical utility of cerebrospinal fluid (CSF) circulating tumor DNA (ctDNA) was underinvestigated in GCLM. METHODS: We retrospectively studied 15 GCLM patients, and all patients had paired primary tumor tissue samples and post-LM CSF samples while 5 patients also had post-LM plasma samples. All samples were analyzed using next-generation sequencing (NGS), and the molecular and clinical features were correlated with clinical outcomes. RESULTS: CSF had higher mutation allele frequency (P = 0.015), more somatic mutations (P = 0.032), and more copy-number variations (P < 0.001) than tumor or plasma samples. Multiple genetic alterations and aberrant signal pathways were enriched in post-LM CSF, including CCNE1 amplification and cell cycle-related genes, and CCNE1 amplification was significantly associated with patients’ overall survival (P = 0.0062). More potential LM progression-related markers were detected in CSF samples than in tumor samples, including PREX2 mutation (P = 0.014), IGF1R mutation (P = 0.034), AR mutation (P = 0.038), SMARCB1 deletion (P < 0.001), SMAD4 deletion (P = 0.0034), and TGF-beta pathway aberration (P = 0.0038). Additionally, improvement in intracranial pressure (P < 0.001), improvement in CSF cytology (P = 0.0038), and relatively low levels of CSF ctDNA (P = 0.0098) were significantly associated with better PFS. Lastly, we reported a GCLM case whose CSF ctDNA dynamic changes were well correlated with his clinical assessment. CONCLUSIONS: CSF ctDNA could more sensitively detect molecular markers and metastasis-related mechanisms than tumor tissues in GCLM patients, and our study sheds light on utilizing CSF ctDNA in prognostic estimation and clinical assessment in GCLM. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-023-04077-8. BioMed Central 2023-05-02 /pmc/articles/PMC10155444/ /pubmed/37131253 http://dx.doi.org/10.1186/s12967-023-04077-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Chen, Xin
Bai, Kaixuan
Zhang, Yu
Xu, Yang
Huo, Yinghao
Wang, Sha
Zou, Yueli
Qi, Xuejiao
Guo, Rongyun
Ou, Qiuxiang
Liu, Dengxiang
Yin, Shaohua
Chen, Shubo
Bu, Hui
Genomic alterations of cerebrospinal fluid cell-free DNA in leptomeningeal metastases of gastric cancer
title Genomic alterations of cerebrospinal fluid cell-free DNA in leptomeningeal metastases of gastric cancer
title_full Genomic alterations of cerebrospinal fluid cell-free DNA in leptomeningeal metastases of gastric cancer
title_fullStr Genomic alterations of cerebrospinal fluid cell-free DNA in leptomeningeal metastases of gastric cancer
title_full_unstemmed Genomic alterations of cerebrospinal fluid cell-free DNA in leptomeningeal metastases of gastric cancer
title_short Genomic alterations of cerebrospinal fluid cell-free DNA in leptomeningeal metastases of gastric cancer
title_sort genomic alterations of cerebrospinal fluid cell-free dna in leptomeningeal metastases of gastric cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10155444/
https://www.ncbi.nlm.nih.gov/pubmed/37131253
http://dx.doi.org/10.1186/s12967-023-04077-8
work_keys_str_mv AT chenxin genomicalterationsofcerebrospinalfluidcellfreednainleptomeningealmetastasesofgastriccancer
AT baikaixuan genomicalterationsofcerebrospinalfluidcellfreednainleptomeningealmetastasesofgastriccancer
AT zhangyu genomicalterationsofcerebrospinalfluidcellfreednainleptomeningealmetastasesofgastriccancer
AT xuyang genomicalterationsofcerebrospinalfluidcellfreednainleptomeningealmetastasesofgastriccancer
AT huoyinghao genomicalterationsofcerebrospinalfluidcellfreednainleptomeningealmetastasesofgastriccancer
AT wangsha genomicalterationsofcerebrospinalfluidcellfreednainleptomeningealmetastasesofgastriccancer
AT zouyueli genomicalterationsofcerebrospinalfluidcellfreednainleptomeningealmetastasesofgastriccancer
AT qixuejiao genomicalterationsofcerebrospinalfluidcellfreednainleptomeningealmetastasesofgastriccancer
AT guorongyun genomicalterationsofcerebrospinalfluidcellfreednainleptomeningealmetastasesofgastriccancer
AT ouqiuxiang genomicalterationsofcerebrospinalfluidcellfreednainleptomeningealmetastasesofgastriccancer
AT liudengxiang genomicalterationsofcerebrospinalfluidcellfreednainleptomeningealmetastasesofgastriccancer
AT yinshaohua genomicalterationsofcerebrospinalfluidcellfreednainleptomeningealmetastasesofgastriccancer
AT chenshubo genomicalterationsofcerebrospinalfluidcellfreednainleptomeningealmetastasesofgastriccancer
AT buhui genomicalterationsofcerebrospinalfluidcellfreednainleptomeningealmetastasesofgastriccancer